BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) was downgraded by analysts at Robert W. Baird from an "outperform" rating to a "neutral" rating. They now have a $72.00 price target on the stock, down previously from $104.00.
LowReport
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) was downgraded by analysts at Robert W. Baird from an "outperform" rating to a "neutral" rating. They now have a $72.00 price target on the stock, down previously from $104.00.
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is now covered by analysts at Evercore ISI. They set an "outperform" rating and a $113.00 price target on the stock.
LowReport
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is now covered by analysts at Evercore ISI. They set an "outperform" rating and a $113.00 price target on the stock.
BioMarin to Present at the BofA Securities 2024 Health Care Conference on Wednesday, May 15 at 10:00am PT / 1:00pm ET, in Las Vegas, NV [Yahoo! Finance]
LowReport
BioMarin to Present at the BofA Securities 2024 Health Care Conference on Wednesday, May 15 at 10:00am PT / 1:00pm ET, in Las Vegas, NV [Yahoo! Finance]
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Don’t Miss Out On The Next BIG Stock Move
"Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ blog email newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our blog below: